MX2011007194A - Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc). - Google Patents

Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc).

Info

Publication number
MX2011007194A
MX2011007194A MX2011007194A MX2011007194A MX2011007194A MX 2011007194 A MX2011007194 A MX 2011007194A MX 2011007194 A MX2011007194 A MX 2011007194A MX 2011007194 A MX2011007194 A MX 2011007194A MX 2011007194 A MX2011007194 A MX 2011007194A
Authority
MX
Mexico
Prior art keywords
nucleosides
combination
treating hcv
cyclosporine derivative
cyclosporine
Prior art date
Application number
MX2011007194A
Other languages
English (en)
Inventor
Samuel Earl Hopkins
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of MX2011007194A publication Critical patent/MX2011007194A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta invención se refiere a combinaciones que comprenden 3-[(3)-2-(N,N-Dimetilamino o una sal, solvato o hidrato farmacéuticamente aceptable de la misma; y ciertos análogos de nucleosido, y su uso en el tratamiento de virus de hepatitis C.
MX2011007194A 2009-01-07 2010-01-07 Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc). MX2011007194A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14306209P 2009-01-07 2009-01-07
US15602609P 2009-02-27 2009-02-27
US25723109P 2009-11-02 2009-11-02
PCT/US2010/020323 WO2010080878A1 (en) 2009-01-07 2010-01-07 Combination of a cyclosporine derivative and nucleosides for treating hcv

Publications (1)

Publication Number Publication Date
MX2011007194A true MX2011007194A (es) 2013-07-12

Family

ID=42084646

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007194A MX2011007194A (es) 2009-01-07 2010-01-07 Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc).

Country Status (11)

Country Link
US (1) US20100227801A1 (es)
EP (1) EP2385833A1 (es)
JP (1) JP2012514606A (es)
CN (1) CN102271688A (es)
AU (1) AU2010203660A1 (es)
BR (1) BRPI1007027A2 (es)
CA (1) CA2748792A1 (es)
IL (1) IL213862A0 (es)
MX (1) MX2011007194A (es)
RU (1) RU2011127079A (es)
WO (1) WO2010080878A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0516737A (pt) * 2004-10-01 2008-04-29 Scynexis Inc método para tratamento ou prevenção da infecção pelo vìrus da hepatite c, usos de um derivado de ciclosporina e de 3-[(r) -2- (n,n-dimetilamino) etiltio-sar] -4- (gama-hidroximetileucina) ciclosporina, ou um sal farmaceuticamente aceitável deste, sal farmaceuticamente aceitável do derivado de ciclosporina, e, hidrato
ATE498630T1 (de) * 2005-09-30 2011-03-15 Scynexis Inc Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
DK2023918T3 (da) 2006-05-19 2011-04-26 Scynexis Inc Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
JP2009539292A (ja) * 2006-06-02 2009-11-12 ぺリション、クロード、アニー 活性電子の管理
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2280989B1 (en) 2008-06-06 2016-02-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CL2009002206A1 (es) * 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
EP2376524B1 (en) * 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
KR101715981B1 (ko) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 뉴클레오사이드 포스포르아미데이트
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
SI2950786T1 (sl) 2013-01-31 2020-03-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
US20140357595A1 (en) * 2013-06-04 2014-12-04 Gilead Pharmasset Llc Methods of preventing and treating recurrence of a hepatitis c virus infection in a subject after the subject has received a liver transplant
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
CN106536538A (zh) * 2014-04-24 2017-03-22 共晶制药股份有限公司 用于治疗黄病毒家族病毒和癌症的2’‑双取代核苷类似物
JP7123264B2 (ja) * 2018-12-14 2022-08-22 中美華世通生物医薬科技（武漢）股▲ふん▼有限公司 Ｓｃｙ－６３５のマレイン酸塩、及び医学におけるその使用
EP4041274B1 (en) * 2019-10-11 2024-05-08 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Ws-635 for use in the treatment of postoperative cognitive dysfunction
EP4431100A1 (en) * 2021-11-12 2024-09-18 National University Corporation Hokkaido University Antiviral agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3521297T3 (pl) * 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
CA2623865A1 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
EP1957510A1 (en) * 2005-12-09 2008-08-20 F.Hoffmann-La Roche Ag Antiviral nucleosides

Also Published As

Publication number Publication date
JP2012514606A (ja) 2012-06-28
IL213862A0 (en) 2011-07-31
WO2010080878A1 (en) 2010-07-15
RU2011127079A (ru) 2013-02-20
AU2010203660A1 (en) 2011-07-28
EP2385833A1 (en) 2011-11-16
BRPI1007027A2 (pt) 2019-09-24
AU2010203660A2 (en) 2011-09-29
US20100227801A1 (en) 2010-09-09
CN102271688A (zh) 2011-12-07
CA2748792A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
MX2011007194A (es) Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc).
MX2011007364A (es) Derivados de fosforamidato de compuestos de nuecleosido de guanosina para tratamiento de infecciones virales.
AU2018256602A1 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
MX350725B (es) Fosforamidatos de nucleosido.
TN2013000421A1 (en) 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2120565A4 (en) CYCLIC NUCLEOSIDE PHOSPHORAMIDATE FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRUS INFECTIONS
MY170941A (en) Pyrimidine derivatives for the treatment of viral infections
HK1123733A1 (en) Viral hepatitis treatment
MX2012011222A (es) Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
IL195025A (en) History of compressed indolubenzazepine with cyclopropyl and pharmaceuticals containing them as an anti-hcv drug
MX2012007076A (es) Terapia combinada de hcv.
MD4403C1 (ro) Compuşi antivirali în bază de dihidroxiizocromen-naftoimidazoli condensaţi
MX2010005355A (es) Derivados de indol sustituidos con 3-aminosulfonilo y metodos de uso de los mismos.
IL232843A0 (en) 4'-azido', 3'-fluoro modified nucleoside derivatives as inhibitors of hepatitis C virus RNA replication
MX2015011473A (es) Compuesto de fosforamidato de nucleosido novedoso y su uso.
GEP20247600B (en) B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
MX2014003180A (es) Metodos para tratar vhc.
RS62943B1 (sr) 2’-supstituisani-n6-supstituisani purinski nukleotidi za lečenje bolesti izazvanih rnk virusima
IL195272A0 (en) Methods and compositions for the treatment of viral infections
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
MX2013011411A (es) Tratamiento para infeccion por el virus de hepatitis b solo o en combinacion con el virus de hepatitis delta y enfermedades hepaticas asociadas.
MX2013000242A (es) Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral.
PH12015502589A1 (en) 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal